Pretreatment lymphocytopenia is an adverse prognostic biomarker in advanced-stage ovarian cancer

Yong Jae Lee, Young Shin Chung, Jung Yun Lee, Eun Ji Nam, Sang Wun Kim, Sunghoon Kim, Young Tae Kim

Research output: Contribution to journalArticle

Abstract

The aim of this study was to investigate the prognostic significance of lymphocytopenia in advanced-stage ovarian cancer. We retrospectively reviewed 506 patients with advanced-stage ovarian cancer at Yonsei Cancer Hospital. This study included two cohorts of patients: a neoadjuvant chemotherapy (NAC) group (N = 247) and a primary debulking surgery (PDS) group (N = 259). The absolute lymphocyte count was recorded before treatment. A receiver operating characteristic (ROC) curve analysis was used to determine the cutoff for defining lymphocytopenia in the NAC cohort and followed by multivariate analysis. Subsequently, lymphocytopenia was assessed in the PDS cohort by multivariate analysis. A further analysis was performed to evaluate the absolute lymphocyte count as a continuous variable. An absolute lymphocyte count of 1.49 × 109/L was determined as the cutoff for the ROC curve analysis in the NAC cohort, and the multivariate analysis revealed that lymphocytopenia was an independent prognostic factor for poor progression-free survival (PFS) [hazard ratio (HR), 1.50; 95% confidence interval (CI), 1.07-2.11] and overall survival (OS) (HR, 2.02; 95% CI, 1.21-3.40). In the PDS cohort, the multivariate analysis showed that lymphocytopenia was an independent prognostic factor for poor PFS (HR, 1.73; 95% CI, 1.20-2.49) and OS (HR, 1.87; 95% CI, 1.27-2.75). The absolute lymphocyte count was a significant factor when analyzed as a continuous variable in both the NAC and PDS cohorts. Pretreatment lymphocytopenia is an independent adverse prognostic factor in patients with advanced-stage ovarian cancer.

Original languageEnglish
Pages (from-to)564-571
Number of pages8
JournalCancer medicine
Volume8
Issue number2
DOIs
Publication statusPublished - 2019 Feb 1

Fingerprint

Lymphopenia
Ovarian Neoplasms
Biomarkers
Lymphocyte Count
Multivariate Analysis
Confidence Intervals
Drug Therapy
Cohort Studies
ROC Curve
Disease-Free Survival
Cancer Care Facilities
Survival

All Science Journal Classification (ASJC) codes

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Cancer Research

Cite this

Lee, Yong Jae ; Chung, Young Shin ; Lee, Jung Yun ; Nam, Eun Ji ; Kim, Sang Wun ; Kim, Sunghoon ; Kim, Young Tae. / Pretreatment lymphocytopenia is an adverse prognostic biomarker in advanced-stage ovarian cancer. In: Cancer medicine. 2019 ; Vol. 8, No. 2. pp. 564-571.
@article{76c46cbdc6ab45218fc292ce1a1dc76d,
title = "Pretreatment lymphocytopenia is an adverse prognostic biomarker in advanced-stage ovarian cancer",
abstract = "The aim of this study was to investigate the prognostic significance of lymphocytopenia in advanced-stage ovarian cancer. We retrospectively reviewed 506 patients with advanced-stage ovarian cancer at Yonsei Cancer Hospital. This study included two cohorts of patients: a neoadjuvant chemotherapy (NAC) group (N = 247) and a primary debulking surgery (PDS) group (N = 259). The absolute lymphocyte count was recorded before treatment. A receiver operating characteristic (ROC) curve analysis was used to determine the cutoff for defining lymphocytopenia in the NAC cohort and followed by multivariate analysis. Subsequently, lymphocytopenia was assessed in the PDS cohort by multivariate analysis. A further analysis was performed to evaluate the absolute lymphocyte count as a continuous variable. An absolute lymphocyte count of 1.49 × 109/L was determined as the cutoff for the ROC curve analysis in the NAC cohort, and the multivariate analysis revealed that lymphocytopenia was an independent prognostic factor for poor progression-free survival (PFS) [hazard ratio (HR), 1.50; 95{\%} confidence interval (CI), 1.07-2.11] and overall survival (OS) (HR, 2.02; 95{\%} CI, 1.21-3.40). In the PDS cohort, the multivariate analysis showed that lymphocytopenia was an independent prognostic factor for poor PFS (HR, 1.73; 95{\%} CI, 1.20-2.49) and OS (HR, 1.87; 95{\%} CI, 1.27-2.75). The absolute lymphocyte count was a significant factor when analyzed as a continuous variable in both the NAC and PDS cohorts. Pretreatment lymphocytopenia is an independent adverse prognostic factor in patients with advanced-stage ovarian cancer.",
author = "Lee, {Yong Jae} and Chung, {Young Shin} and Lee, {Jung Yun} and Nam, {Eun Ji} and Kim, {Sang Wun} and Sunghoon Kim and Kim, {Young Tae}",
year = "2019",
month = "2",
day = "1",
doi = "10.1002/cam4.1956",
language = "English",
volume = "8",
pages = "564--571",
journal = "Cancer Medicine",
issn = "2045-7634",
publisher = "John Wiley and Sons Ltd",
number = "2",

}

Pretreatment lymphocytopenia is an adverse prognostic biomarker in advanced-stage ovarian cancer. / Lee, Yong Jae; Chung, Young Shin; Lee, Jung Yun; Nam, Eun Ji; Kim, Sang Wun; Kim, Sunghoon; Kim, Young Tae.

In: Cancer medicine, Vol. 8, No. 2, 01.02.2019, p. 564-571.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Pretreatment lymphocytopenia is an adverse prognostic biomarker in advanced-stage ovarian cancer

AU - Lee, Yong Jae

AU - Chung, Young Shin

AU - Lee, Jung Yun

AU - Nam, Eun Ji

AU - Kim, Sang Wun

AU - Kim, Sunghoon

AU - Kim, Young Tae

PY - 2019/2/1

Y1 - 2019/2/1

N2 - The aim of this study was to investigate the prognostic significance of lymphocytopenia in advanced-stage ovarian cancer. We retrospectively reviewed 506 patients with advanced-stage ovarian cancer at Yonsei Cancer Hospital. This study included two cohorts of patients: a neoadjuvant chemotherapy (NAC) group (N = 247) and a primary debulking surgery (PDS) group (N = 259). The absolute lymphocyte count was recorded before treatment. A receiver operating characteristic (ROC) curve analysis was used to determine the cutoff for defining lymphocytopenia in the NAC cohort and followed by multivariate analysis. Subsequently, lymphocytopenia was assessed in the PDS cohort by multivariate analysis. A further analysis was performed to evaluate the absolute lymphocyte count as a continuous variable. An absolute lymphocyte count of 1.49 × 109/L was determined as the cutoff for the ROC curve analysis in the NAC cohort, and the multivariate analysis revealed that lymphocytopenia was an independent prognostic factor for poor progression-free survival (PFS) [hazard ratio (HR), 1.50; 95% confidence interval (CI), 1.07-2.11] and overall survival (OS) (HR, 2.02; 95% CI, 1.21-3.40). In the PDS cohort, the multivariate analysis showed that lymphocytopenia was an independent prognostic factor for poor PFS (HR, 1.73; 95% CI, 1.20-2.49) and OS (HR, 1.87; 95% CI, 1.27-2.75). The absolute lymphocyte count was a significant factor when analyzed as a continuous variable in both the NAC and PDS cohorts. Pretreatment lymphocytopenia is an independent adverse prognostic factor in patients with advanced-stage ovarian cancer.

AB - The aim of this study was to investigate the prognostic significance of lymphocytopenia in advanced-stage ovarian cancer. We retrospectively reviewed 506 patients with advanced-stage ovarian cancer at Yonsei Cancer Hospital. This study included two cohorts of patients: a neoadjuvant chemotherapy (NAC) group (N = 247) and a primary debulking surgery (PDS) group (N = 259). The absolute lymphocyte count was recorded before treatment. A receiver operating characteristic (ROC) curve analysis was used to determine the cutoff for defining lymphocytopenia in the NAC cohort and followed by multivariate analysis. Subsequently, lymphocytopenia was assessed in the PDS cohort by multivariate analysis. A further analysis was performed to evaluate the absolute lymphocyte count as a continuous variable. An absolute lymphocyte count of 1.49 × 109/L was determined as the cutoff for the ROC curve analysis in the NAC cohort, and the multivariate analysis revealed that lymphocytopenia was an independent prognostic factor for poor progression-free survival (PFS) [hazard ratio (HR), 1.50; 95% confidence interval (CI), 1.07-2.11] and overall survival (OS) (HR, 2.02; 95% CI, 1.21-3.40). In the PDS cohort, the multivariate analysis showed that lymphocytopenia was an independent prognostic factor for poor PFS (HR, 1.73; 95% CI, 1.20-2.49) and OS (HR, 1.87; 95% CI, 1.27-2.75). The absolute lymphocyte count was a significant factor when analyzed as a continuous variable in both the NAC and PDS cohorts. Pretreatment lymphocytopenia is an independent adverse prognostic factor in patients with advanced-stage ovarian cancer.

UR - http://www.scopus.com/inward/record.url?scp=85061907014&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85061907014&partnerID=8YFLogxK

U2 - 10.1002/cam4.1956

DO - 10.1002/cam4.1956

M3 - Article

C2 - 30652425

AN - SCOPUS:85061907014

VL - 8

SP - 564

EP - 571

JO - Cancer Medicine

JF - Cancer Medicine

SN - 2045-7634

IS - 2

ER -